1st Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$2,440,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

9 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Pharmaceutical supply chain incentives R&D Amortization U.S. Corporate Tax

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Biosimilars Drug Pricing Fiscal year 2024 Appropriations H.R.5376, Inflation Reduction Act Implementation Importation Value of Medicine

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Executive Office of the President (EOP); White House Office; SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5376 (118th)

Copyright/Patent/Trademark CPT

Antitrust Legislation Bayh-Dole Act/March-In Rights Biopharmaceutical Intellectual Property Biosimilars BPCIA Compulsory licenses Data Exclusivity H.R. 2883/S. 148, Stop Stalling Access to Affordable Medications H.R. 2884/S. 150, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891/S. 142, the Preserve Access to Affordable Generics and Biosimilars Act H.R. 5376, Inflation Reduction Act Implementation S. 79, Patent Coordination and Improvement Act of 2023 S. 113, Prescription Pricing for the People Act of 2023 Intellectual Property Issues in Response to coronavirus Inter Parties Review at PTO Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO Patents S.1435, Affordable Prescriptions for Patients Act of 2021 Section 101 WTO TRIPS Waiver

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: SENATE; Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES

Bills named: S. 79 (118th), S. 1435 (118th), H.R. 2883 (118th), H.R. 2891 (118th), S. 142 (118th), H.R. 2884 (118th), S. 148 (118th), H.R. 5376 (118th), S. 113 (118th), S. 150 (118th)

Health Issues HCR

340B Drug Discount Program Accelerated Approval Alternative Funding Programs Biosimilar approval and reimbursement policy issues BLOCKING Act Cancer Moonshot Cell, gene and radioligand therapies Co-pay accumulator programs COVID-19 Diversity in Clinical Trials Drug cost and pricing policy issues Drug shortages policy issues FDA modernization policy issues Foreign manufacturing policy issues Genetically Targeted Technologies H.R, 2534 - Preserving Rules Ordered for the Entities Covered Through (PROTECT) 340B Act H.R. 5376 - Inflation Reduction Act Implementation H.R. 5416, The Give Kids a Chance Act The Medicaid VBPs for Patients (MVP) Act H.R. 830, HELP Co-pays Act H.R. 1613, The Drug Price Transparency in Medicaid Act Intellectual property Notice of Benefit Payment Parameters (NBPP) Orphan Drugs Outcomes based contracting/value based arrangements Patient assistance program policy issues PDUFA, BSUFA, GDUFA Pharmaceutical quality Pharmaceutical supply chain Pharmacy benefit manager policy issues Priority Review Voucher (PRV) Regulatory efficiencies policy issues S. 2837, 340B Accountability Act 2021 S. 476, The Maintaining Investments in New Innovations (MINI) Act S.127, The Pharmacy Benefit Manager Transparency Act of 2023 Transparency policy issues Utilization management policies Vaccines

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: White House Office; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Executive Office of the President (EOP); SENATE

Bills named: H.R. 1613 (118th), S. 476 (118th), H.R. 5416 (118th), S. 127 (118th), H.R. 5376 (118th), H.R. 830 (118th), S. 2837 (118th)

Medicare/Medicaid MMM

ASP reporting policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Drug Pricing H.R. 5376, Inflation Reduction Act Innovative Pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Inflation Reduction Act Impact on Innovative Pharmaceuticals and implementation Medicaid Medicare Part A, B and D Medicare Part D Negotiations Medicare Part D Re-design and out of pocket cap National coverage determination policies Outcomes based Contracting/value based arrangements Patient Cost-Sharing and Smoothing Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals Transparency policy issues Advanced Safe Testing at Residence Telehealth Act of 2023 S. 476, The Maintaining Investments in New Innovations (MINI) Act

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); White House Office

Bills named: S. 476 (118th), H.R. 5376 (118th)

Trade (domestic/foreign) TRD

Access to Medicines Issues Biopharmaceutical Innovation Policies Free Trade Agreements - Intellectual Property and Transparency Provisions Global Health Issues India, China and Canada IP and Market Access Issues Intellectual property International Market Access and Intellectual Property Issues Pharmaceutical Supply Chain Pricing and reimbursement policy issues Supply chain and China Task Force policy issues Trade Policy US Swiss Trade Relations US Switzerland Mutual Recognition Agreement on GMP WTO IP Waiver

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); White House Office; U.S. Trade Representative (USTR); SENATE; State, Dept of (DOS); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); Executive Office of the President (EOP)

Veterans VET

Health care collaboration opportunities

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); SENATE

Labor Issues/Antitrust/Workplace LBR

Non-competes policies Federal Trade Commission's Non-Compete Clause Proposed Rule

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Manufacturing MAN

H.R, 555 Securing America's Vaccines for Emergencies Act of 2023

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.